Perrigo Co. (PRGO) said Tuesday it has received final approval for its abbreviated new drug application for fluocinonide cream 0.1%, the generic equivalent to Vanos® Cream 0.1%.
Perrigo said it was awarded 180-days of generic drug exclusivity. Perrigo had previously resolved litigation with the brand and has commenced shipment of the product.
Vanos® Cream 0.1% (fluocinonide cream 0.1%) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older and has estimated annual sales of about $107 million.
For comments and feedback: editorial@rttnews.com